

# Co-occurrence of radiological signs of Marchiafava-Bignami disease and alcohol-related cerebellar degeneration

## Co-ocorrência de sinais radiológicos da doença de Marchiafava-Bignami e da degeneração cerebelar relacionada ao álcool

Alberto Pereira Firmino Filho<sup>1</sup>, Maria Weryca de Souza Belo Silva<sup>1</sup>, Beatriz Barbosa<sup>2</sup>, Enrique Neves<sup>2</sup>, Letícia Ellen Pereira<sup>2</sup>, Thadeu Alexandre Paulino Sousa<sup>3</sup>, Katie Moraes de Almondes<sup>2,4,5</sup>, Clécio de Oliveira Godeiro Júnior<sup>6</sup>, Rodrigo Alencar e Silva<sup>6</sup>

A 53-year-old man with a history of chronic alcohol consumption developed anterograde amnesia, accompanied by visual and auditory hallucinations and behavioral changes. Cognitive evaluation revealed mild impairment in the frontal battery and significant decline in episodic memory (Table 1). On physical examination, the patient presented asymmetric cerebellar ataxia, more pronounced on the left side, along with global areflexia. External eye movements were preserved, and no nystagmus was observed.

Brain magnetic resonance imaging (MRI) reveals global atrophy, predominantly affecting the cerebellar vermis, with three lesions exhibiting hypointensity on T1 and

hyperintensity on T2 in the splenium of the corpus callosum (Figures 1 and 2). No restriction in water diffusion or enhance with gadolinium was noted.

Marchiafava Bignami Disease (MBD) is a disorder associated with vitamin deficiency due to chronic alcohol abuse or malnutrition. It classically leads to signal changes in the corpus callosum, as seen on MRI, associated with neuropsychiatric symptoms<sup>1</sup>. Despite its rarity, knowledge of its clinical and radiological aspects is crucial for early suspicion and accurate diagnosis, which can help prevent negative outcomes.

Some authors advocate classifying the clinical presentation into at least two

This study was conducted by Universidade Federal do Rio Grande do Norte, Natal RN, Brazil.

<sup>1</sup>Universidade Federal do Rio Grande do Norte, Hospital Universitário Onofre Lopes, Natal RN, Brazil.

<sup>2</sup>Hospital Universitário Onofre Lopes, Serviço de Neuropsicologia do Envelhecimento, Natal RN, Brazil.

<sup>3</sup>Hospital Monsenhor Walfredo Gurgel, Natal RN, Brazil.

<sup>4</sup>Universidade Federal do Rio Grande do Norte, Departamento de Psicologia, Natal RN, Brazil.

<sup>5</sup>Universidade Federal do Rio Grande do Norte, Programa de Pós-Graduação em Psicobiologia, Natal RN, Brazil.

<sup>6</sup>Universidade Federal do Rio Grande do Norte, Hospital Universitário Onofre Lopes, Departamento de Neurologia, Natal RN, Brazil.

**Correspondence:** Rodrigo Alencar e Silva; Email: [alencar-rodrigo@hotmail.com](mailto:alencar-rodrigo@hotmail.com).

**Disclosure:** The authors report no conflicts of interest.

**Funding:** none

**Editor-in-Chief:** Sonia M. D. Brucki.

**Associate Editor:** Leandro Tavares Lucato.

Received on September 08, 2024; Received in its final form on November 18, 2024; Accepted on November 28, 2024.




**Table 1.** Neuropsychological assessment.

| 53 years old, 7 years of schooling, retired (bricklayer) |                                    |                                            |                                                                                                                  |            |
|----------------------------------------------------------|------------------------------------|--------------------------------------------|------------------------------------------------------------------------------------------------------------------|------------|
| Tests                                                    | Patient's score                    | Z score                                    | Interpretation                                                                                                   | Date       |
| Frontal Assessment Battery                               | 15/18                              |                                            | Mild Significant Impairment                                                                                      | 07/04/2024 |
| Apraxia Tests                                            | 22/22                              |                                            | Without apraxia<br>Without astereognosis                                                                         | 07/04/2024 |
| Digit Span                                               | Forward Span<br>total:7<br>span:5  | Forward Span<br>total:0.06<br>span:0.09    | No impairment evidenced in<br>attention or working memory.                                                       | 07/04/2024 |
|                                                          | Backward Span<br>total:4<br>span:3 | Backward Span<br>total:-0.25<br>span:-0.41 |                                                                                                                  |            |
| Rey Auditory Verbal Learning<br>Test (RAVLT)             | ΣA1A5: 17                          | ΣA1A5: -2.95                               | Patient showed clinically<br>significant decline in<br>episodic memory.                                          | 07/04/2024 |
|                                                          | A7: 4                              | A7: -1.71                                  |                                                                                                                  |            |
|                                                          | Recognition: -1                    | Recognition: -2.28                         |                                                                                                                  |            |
|                                                          | Learning Over Trials: 17           | Learning Over Trials: 0.18                 |                                                                                                                  |            |
|                                                          | Forgetting Speed Index: 1.33       | Forgetting Speed Index: 1.63158            |                                                                                                                  |            |
| The Stick Design Test                                    | 12/12                              |                                            | No evident impairment in<br>visuoconstructive skills.                                                            | 07/04/2024 |
| Five Digit Test                                          | Counting<br>time: 55<br>errors: 0  | Counting<br>time: -3,87<br>errors: 0       | Inconclusive result. Patient<br>was unable to complete the<br>testing due to difficulties with<br>visual acuity. | 07/04/2024 |
| The Geriatric Depression<br>Scale (GDS-15)               | 9/15                               |                                            | Mild Depressive Symptoms                                                                                         | 07/25/2024 |
| Boston Naming Test (BNT) -<br>Reduced Version            | 14/15                              | 0.52941                                    | No apparent impairment in<br>semantic memory                                                                     | 07/25/2024 |
| F-A-S Phonemic and<br>Semantic Verbal Fluency Test       | Semantic: 17                       | Semantic: 0.30238                          | Without evidence of impairment<br>in semantic memory nor<br>executive functions                                  | 07/25/2024 |
|                                                          | Phonemic: 36                       | Phonemic: 0.48704                          |                                                                                                                  |            |
| Psychological Battery for<br>Attention Assessment (BPA)  |                                    |                                            | The patient was unable to<br>perform due to severe tremors.                                                      | 07/25/2024 |
| Benton Visual Retention<br>Test (BVRT)                   |                                    |                                            | The patient was unable to<br>perform due to severe action<br>tremors and low visual acuity                       | 07/25/2024 |


distinct syndromes, based on the time of onset, severity of symptoms, as well as neuroimaging findings. In this sense, an acute, more severe form is characterized by faster progression and greater involvement of the level of consciousness, often associated with pyramidal symptoms, seizures, and eventually death. Chronic cases, such as the one described above, typically present with slower clinical onset, gait disturbances, dysarthria, interhemispheric disconnection, less pronounced involvement of awareness, and better prognosis<sup>2,3</sup>.

The typical presentation involves lesions with a cystic appearance or an edema/demyelinating substrate, generally located in the corpus callosum, which may also affect the deep white matter. The number and characteristics of the lesions may change with disease progression. Fewer lesions, restricted diffusion, and gadolinium enhancement typically indicate an acute process<sup>2,4,5</sup>.

Chronic alcohol consumption has long been associated to structural damage to brain tissue, leading to a variety of neuroimaging patterns, with MBD being one



**Figure 1.** Brain magnetic resonance imaging sagittal T1 sequence, post-contrast, showing hypointensity of the splenium lesion and cerebellar vermis atrophy, no enhancement by the contrast.



**Figure 2.** Brain magnetic resonance imaging axial and coronal T2 sequences showing hyperintense lesions, without mass effect, involving the splenium of the corpus callosum.

of the many possible complications of this deleterious behavior. A classic feature in patients with chronic alcoholism is brain volume loss, particularly in the cerebellum and frontal lobe. In addition, involvement of the pontocerebellar fibers may lead to pontine atrophy. Less commonly, striatal degeneration may be observed in some subjects, and the combination of MBD and Wernicke encephalopathy has also been described. This supports the statement that, as in the case described above, other findings associated with alcohol abuse, such as cortical and cerebellar atrophy, may be present simultaneously<sup>4,6</sup>.

This overlap with other, sometimes nonspecific, radiological findings, may hinder the suspicion of MBD and highlights the importance of considering alternative diagnosis. Wernicke encephalopathy usually presents with involvement of the medial thalamic nuclei, hypothalamus, mamillary bodies, and periaqueductal grey matter. Pontine and extrapontine myelinolysis can also be differentiated by the involvement of the central pons, basal ganglia, thalamus, lateral geniculate body, cerebellum, and cerebral cortex. Ischemic stroke, contusion, multiple sclerosis, lymphoma, and other diseases with preference for the deep white matters and corpus callosum may mimic MBD syndrome, but usually can be differentiated by the asymmetrical appearance of their lesions, once symmetry is a key feature for this condition<sup>7,8</sup>.

The cornerstone of treatment is supplementation of complex B vitamins, especially thiamine, as well as cessation of alcohol consumption along with rehabilitation therapy. The use of high-dose corticosteroids in acute patients has been reported as a safe strategy with positive outcomes<sup>2,5,9,10</sup>.

In the clinical case described, the patient was hospitalized and started on intravenous thiamine replacement, medications for alcohol withdrawal syndrome, as well as treatments to manage symptoms of depression/anxiety. In subsequent follow-up visits, the decision was made to refer him for joint follow-up with outpatient psychiatric care, while continuing surveillance with periodic exams and vitamin replacement, despite only slight improvement in neurological symptoms.

## AUTHORS' CONTRIBUTIONS

Conceptualization: APFF, MWSBS, COGJ, RAS; Data curation: APFF, MWSBS, BB, EN, LEP, TAPS, RAS; Formal analysis: APFF, BB, TAPS, KMA, COGJ, RAS; Investigation: APFF, MWSBS, EN, LEP, TAPS, KMA, COGJ, RAS; Methodology: APFF, MWSBS, BB, EN, LEP, KMA, COGJ, RAS; Project administration: KMA, RAS; Supervision: KMA, COGJ, RAS; Validation: KMA, COGJ, RAS; Visualization: KMA, RAS; Writing – original draft: APFF, MWSBS, BB, EN; Writing – review & editing: COGJ, RAS.

## REFERENCES

1. Sato Y, Tabira T, Tateishi J. Marchiafava-Bignami disease, striatal degeneration, and other neurological complications of chronic alcoholism in a Japanese. *Acta Neuropathol.* 1981;53(1):15-20. <https://doi.org/10.1007/BF00697179>
2. Parmanand TH. Marchiafava-Bignami disease in chronic alcoholic patient. *Radiol Case Rep.* 2016;11(3):234-7. <https://doi.org/10.1016/j.radcr.2016.05.015>
3. Heinrich A, Runge U, Khaw AV. Clinico-radiologic subtypes of Marchiafava-Bignami disease. *J Neurol.* 2004;251(9):1050-9. <https://doi.org/10.1007/s00415-004-0566-1>
4. Hillbom M, Saloheimo P, Fujioka S, Wszolek ZK, Juvela S, Leone MA. Diagnosis and management of Marchiafava-Bignami disease: a review of CT/MRI confirmed cases. *J Neurol Neurosurg Psychiatry.* 2014;85(2):168-73. <https://doi.org/10.1136/jnnp-2013-305979>

5. Carrilho PEM, Santos MBM, Piasecki L, Jorge AC. Doença de Marchiafava-Bignami: uma rara entidade com prognóstico sombrio. *Rev Bras Ter Intensiva*. 2013;25(1):68-72. <https://doi.org/10.1590/S0103-507X2013000100013>
6. Karoly HC, Kirk-Provencher KT, Schacht JP, Gowin JL. Alcohol and brain structure across the lifespan: a systematic review of large-scale neuroimaging studies. *Addict Biol*. 2024;29(9):e13439. <https://doi.org/10.1111/adb.13439>
7. Xiaoyu D, Chaobo B, Nao J. Clinical and radiological features of Marchiafava-Bignami disease. *Medicine (Baltimore)*. 2018;97(5):e9626. <https://doi.org/10.1097/MD.00000000000009626>
8. Johkura K, Naito M, Naka T. Cortical involvement in Marchiafava-Bignami disease. *AJNR Am J Neuroradiol*. 2005;26(3):670-3. PMID: 15760886.
9. Shen YY, Chen-Guang Z, Han N, Liang XM, Deng YQ. Clinical and neuroradiological features of 15 patients diagnosed with Marchiafava-Bignami disease. *Chin Med J (Engl)*. 2019;132(15):1887-9. <https://doi.org/10.1097/CM9.0000000000000334>
10. Zhang YL, Ran C, Xu C, Li W. Clinico-radiologic subtypes and therapeutic observation of acute Marchiafava-Bignami disease. *Sci Rep*. 2023;13(1):18516. <https://doi.org/10.1038/s41598-023-45431-6>